Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2009-12-30 Declaration of Voting R…
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2009
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly announces a change in the 'NEW NUMBER OF SHARES AND VOTES' due to a rights issue, stating the total number of shares has increased. This directly relates to a change in the company's capital structure or share count. Reviewing the definitions, 'Share Issue/Capital Change (Code: SHA)' is the most appropriate category, as it covers announcements regarding new share issues or capital changes. It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it concerns a specific capital event.
2009-12-30 English
Declaration of Voting Results & Voting Rights Announcements 2009
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a short announcement dated December 30, 2009, titled 'ÄNDRING AV ANTALET AKTIER OCH RÖSTER I KARO BIO AB (PUBL)' (Change in the Number of Shares and Votes in Karo Bio AB (Publ)). It explicitly states that the total number of shares has changed due to a rights issue ('företrädesemission'). This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). Although it is a regulatory announcement, SHA is more specific than the general RNS fallback.
2009-12-30 Swedish
Share Issue/Capital Change 2009
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing that a rights issue (nyemission) for Karo Bio AB was heavily oversubscribed ('kraftigt övertecknad'). It details the subscription rate, the allocation of unsubscribed shares, and the resulting changes in the number of shares and share capital. This content directly relates to fundraising, financing activities, and capital structure changes. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). The document is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report publication (RPA), as it contains the substantive details of the financing event itself.
2009-12-09 Swedish
Share Issue/Capital Change 2009
Share Issue/Capital Change Classification · 99% confidence The document is an announcement titled "KARO BIO'S RIGHTS ISSUE SUBSTANTIALLY OVERSUBSCRIBED." It details the results of a rights issue (a form of capital raising/financing activity), including the oversubscription percentage, the number of shares subscribed, and the resulting increase in share capital. This content directly relates to changes in the company's capital structure and fundraising efforts. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific corporate finance event.
2009-12-09 English
Capital/Financing Update 2009
Capital/Financing Update Classification · 95% confidence The document is a press release dated November 27, 2009, announcing that Karo Bio AB has 'published a supplement to the previously published prospectus pertaining to the company's rights issue.' It details where the prospectus supplement can be downloaded and discusses the right of withdrawal triggered by this publication. This is not the full financial report (10-K or IR), nor is it a general earnings release (ER). It is an announcement specifically about the publication of a key offering document (a prospectus supplement related to a rights issue/capital activity). Since it announces the publication of a document and relates to financing/capital structure changes, it strongly aligns with either 'Report Publication Announcement' (RPA) or 'Capital/Financing Update' (CAP). Given the core subject is the publication of a prospectus supplement for a rights issue, 'CAP' (Capital/Financing Update) is the most specific fit, as the publication is a direct consequence of the financing activity. However, the text explicitly states the prospectus supplement 'is published' and provides links, fitting the RPA definition of announcing the release of a document. Since the document's primary function is to inform the market that the prospectus supplement is now available, RPA is a strong candidate. If the document were the prospectus itself, it would be CAP. As it is the announcement of the prospectus publication, RPA is chosen, although CAP is closely related. Given the context of a rights issue, CAP is arguably more descriptive of the underlying event being communicated, but RPA captures the nature of the communication itself (announcing publication). I will lean towards RPA as it focuses on the act of publication, which is a common trigger for RPA classification when the actual detailed report is external.
2009-11-27 English
Capital/Financing Update 2009
Capital/Financing Update Classification · 95% confidence The document is a press release from Karo Bio AB dated November 27, 2009, announcing the publication of a supplementary prospectus ('tilläggsprospekt') related to a rights issue ('nyemission'). The core action described is the *publication* of a document (the supplementary prospectus) which details changes related to the financing activity (the rights issue). The text explicitly mentions that the supplementary prospectus contains information regarding Merck & Co., Inc.'s plans, and it provides instructions on where to obtain the prospectus (Finansinspektionen, Karo Bio's website) and details about the right to revoke previous subscriptions. Since the document itself is an announcement about the release of a formal offering document (the prospectus) and details related to that offering, it strongly aligns with a Capital/Financing Update (CAP) or potentially a Report Publication Announcement (RPA) if the focus was purely on the release mechanism. However, because the content is centered on the details of the rights issue, the associated withdrawal rights, and the subsequent delay of preliminary results, 'Capital/Financing Update' (CAP) is the most appropriate primary classification for the underlying event being communicated. Given the document's length (5144 chars) and its function as a detailed update on the financing terms and investor rights following the prospectus publication, it goes beyond a simple RPA, but the core subject is the financing activity.
2009-11-27 Swedish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.